Immunotherapy in Melanoma | Specialty

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

November 20th 2015

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

Nivolumab Survival Benefit Sustained in Long-Term Melanoma Data

November 20th 2015

Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.

Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma

November 20th 2015

With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.

Dr. Michael Krauthammer on NF1 Mutations in Melanoma

November 20th 2015

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma

November 19th 2015

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Researchers Seek to Improve Responses With Checkpoint Inhibitors

November 19th 2015

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

Dr. Sancy Leachman on Helping Patients Identify Melanoma Recurrences

November 19th 2015

Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.

Sheri Holmen on Understanding Drivers of Melanoma Metastasis

November 19th 2015

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

Avelumab Receives Breakthrough Therapy Designation for Merkel Cell Carcinoma

November 18th 2015

The FDA has granted a breakthrough therapy designation to avelumab as a potential treatment for patients with metastatic Merkel cell carcinoma following progression on at least one prior chemotherapy regimen.

FDA Approves New Melanoma Combo, ASH Abstracts Released, Early Ovarian Cancer Data, and More

November 13th 2015

FDA Approves Vemurafenib/Cobimetinib Combo for Melanoma

November 10th 2015

The FDA has approved the combination of vemurafenib and cobimetinib as a treatment for patients with metastatic or unresectable BRAF V600E/K mutation-positive melanoma.

Adjuvant Ipilimumab Approval, Two Breakthrough Designations, and More

November 9th 2015

Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval

November 6th 2015

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes.

BRAF/MEK Combination Highly Effective in Melanoma

November 6th 2015

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

Dr. Weber on Dabrafenib/Trametinib Approval for Melanoma

November 6th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Targeted Therapy Combinations Still Key in Metastatic Melanoma

November 5th 2015

Combinations of targeted therapies continue to advance toward full regulatory approval for patients with metastatic or unresected melanoma, given the substantial benefits seen with these agents.

FDA Approves Adjuvant Ipilimumab in Melanoma

October 28th 2015

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

FDA Approves T-VEC for Advanced Melanoma

October 27th 2015

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

CHMP Recommends T-VEC Approval for Melanoma

October 23rd 2015

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.